Hussman Strategic Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Hussman Strategic Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Sell	63,000 -105,000	-63%	-$2.31M	0.37%	132
2026 Q1	$3.74M	Buy	168,000 +21,000	+14%	+$502K	0.81%	12
2025 Q4	$3.93M	Buy	147,000 +21,000	+17%	+$502K	0.95%	7
2025 Q3	$2.69M	Buy	+126,000	New	+$2.98M	0.58%	50
2024 Q3	–	Sell	-42,000	Closed	-$683K	–	220
2024 Q2	$683K	Hold	42,000	–	–	0.19%	172
2024 Q1	$777K	Hold	42,000	–	–	0.18%	158
2023 Q4	$1.32M	Hold	42,000	–	–	0.3%	134
2023 Q3	$875K	Sell	42,000 -20,000	-32%	-$543K	0.17%	213
2023 Q2	$1.48M	Sell	62,000 -31,000	-33%	-$689K	0.27%	168
2023 Q1	$1.75M	Buy	+93,000	New	+$1.77M	0.27%	151

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hussman Strategic Advisors's ACAD Position: Q2 2026 in Review

Hussman Strategic Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 63% in Q2 2026, selling an estimated $2.31M and leaving 63,000 shares worth $1.59M. The position accounts for 0.37% of the portfolio, ranked #132.

Hussman Strategic Advisors first reported a position in ACAD in Q1 2023 and has held it in 10 quarters since. The position peaked at $3.93M in Q4 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Hussman Strategic Advisors held 63,000 shares of Acadia Pharmaceuticals worth $1.59M as of Q2 2026.
Hussman Strategic Advisors sold 105,000 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.31M.
Acadia Pharmaceuticals made up 0.37% of Hussman Strategic Advisors's portfolio in Q2 2026, its #132 holding.
Hussman Strategic Advisors first reported a position in Acadia Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
Hussman Strategic Advisors's Acadia Pharmaceuticals position peaked at $3.93M in Q4 2025.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.